Multifocal motor neuropathy (MMN) is a rare, chronic autoimmune disorder that affects motor nerves, leading to progressive muscle weakness. As per Nikhil Khandelwal et al., 2025, the disease accounts for around 1 case per 100,000 individuals globally. According to the multifocal motor neuropathy pipeline analysis by Expert Market Research, there is a growing focus on developing targeted immunotherapies and antibody-based treatments to manage the disease more effectively. The introduction of advanced MMN therapeutics, including monoclonal antibodies, is expected to drive market growth in the coming years. Increased research funding and rising awareness are also key factors supporting the expanding drug development pipeline.
Major companies involved in the multifocal motor neuropathy pipeline analysis include Takeda, Dianthus Therapeutics, and others.
Leading drugs currently in the pipeline include TAK-771, DNTH103, and others.
Rising research on immune-mediated neuropathies, increased clinical trials of monoclonal antibodies, and advancements in gene therapy are expected to significantly drive the growth of the multifocal motor neuropathy drug pipeline.
The Multifocal Motor Neuropathy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into multifocal motor neuropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for multifocal motor neuropathy. The multifocal motor neuropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The multifocal motor neuropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with multifocal motor neuropathy thy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to multifocal motor neuropathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Multifocal motor neuropathy (MMN) is a rare, progressive neurological disorder that affects the peripheral nerves, primarily causing muscle weakness in the arms and hands. It occurs when the body’s immune system mistakenly attacks the myelin sheath protecting motor nerves, disrupting nerve signals without significantly affecting sensory nerves.
Multifocal motor neuropathy is treated with intravenous immunoglobulin (IVIG) therapy, which helps modulate immune response and improve muscle strength. Corticosteroids and immunosuppressive agents may also be considered in some cases. Takeda’s GAMMAGARD LIQUID® was reaffirmed by the U.S. FDA as the only IVIG therapy approved for maintenance treatment in adults with multifocal motor neuropathy, aimed at improving muscle strength and reducing disability.
The global prevalence of multifocal motor neuropathy (MMN) is estimated at less than 1 in 100,000 individuals, with higher incidence reported in males aged 30 to 50 years. Recent pipeline analysis indicates ongoing research targeting immunomodulatory therapies. The limited patient population poses development challenges yet increasing clinical awareness and early diagnosis are expected to drive demand for effective treatment options.
This section of the report covers the analysis of multifocal motor neuropathy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The multifocal motor neuropathy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phases II and III cover a major share of the total multifocal motor neuropathy clinical trials, with around 50% each. This reflects a growing mid-to-late-stage development focus, indicating a strong commitment toward advancing therapies. The progress in these phases highlights the potential for effective treatment options, positively impacting market growth and addressing unmet patient needs.
The drug molecule categories covered under the multifocal motor neuropathy pipeline analysis include small molecule, oligonucleotide, and peptide. The multifocal motor neuropathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for multifocal motor neuropathy. Monoclonal antibody-based therapies are emerging in the multifocal motor neuropathy drug pipeline to provide targeted immune modulation. For instance, ARGX-117 (empasiprubart), an anti-complement C2 humanized monoclonal antibody, is currently under clinical evaluation. It aims to reduce complement-mediated nerve damage by selectively inhibiting the classical complement pathway, potentially improving motor function and reducing disease progression.
The EMR report for the multifocal motor neuropathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed multifocal motor neuropathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in multifocal motor neuropathy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for multifocal motor neuropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of multifocal motor neuropathy drug candidates.
TAK-771 is a subcutaneous immunoglobulin therapy combined with recombinant human hyaluronidase, currently being evaluated by Takeda in a Phase 3 study for Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). The study aims to assess the efficacy, safety, and tolerability of TAK-771 in controlling disease symptoms. Participants are receiving infusions every 2 to 4 weeks over a 45-month period.
DNTH103, developed by Dianthus Therapeutics, is currently undergoing a Phase 2 clinical trial to assess its safety, tolerability, pharmacometrics, and efficacy in adults with multifocal motor neuropathy (MMN). This investigational monoclonal antibody targets the classical complement pathway by inhibiting only active C1s protein. Engineered with YTE technology, DNTH103 is offering extended half-life and subcutaneous dosing as infrequently as once every two weeks.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Multifocal Motor Neuropathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for multifocal motor neuropathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into multifocal motor neuropathy collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share